These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38606836)

  • 41. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daptomycin and Ceftaroline Combination Therapy in Complicated Endovascular Infections Caused by Methicillin-Resistant Staphylococcus epidermidis.
    Policarpo S; Duro R; Pereira NR; Santos L
    Cureus; 2024 Feb; 16(2):e54134. PubMed ID: 38487127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations.
    Martins FS; Martins JES; Severino P; Annaert P; Sy SKB
    Br J Clin Pharmacol; 2023 Sep; 89(9):2726-2738. PubMed ID: 37005335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant
    Bakthavatchalam YD; Rao SV; Isaac B; Manesh A; Nambi S; Swaminathan S; Nagvekar V; Nangia V; John PV; Veeraraghavan B
    Indian J Med Microbiol; 2019; 37(4):478-487. PubMed ID: 32436868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance.
    Abate G; Wang G; Frisby J
    Ann Pharmacother; 2022 Dec; 56(12):1339-1348. PubMed ID: 35300514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
    Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
    Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia.
    Burnett YJ; Echevarria K; Traugott KA
    Ann Pharmacother; 2016 Dec; 50(12):1051-1059. PubMed ID: 27520326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimicrobial Resistance and Molecular Epidemiology of Staphylococcus aureus Causing Bloodstream Infections at Ruijin Hospital in Shanghai from 2013 to 2018.
    Gu F; He W; Xiao S; Wang S; Li X; Zeng Q; Ni Y; Han L
    Sci Rep; 2020 Apr; 10(1):6019. PubMed ID: 32265473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
    Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES
    Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
    Nigo M; Diaz L; Carvajal LP; Tran TT; Rios R; Panesso D; Garavito JD; Miller WR; Wanger A; Weinstock G; Munita JM; Arias CA; Chambers HF
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28232309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia.
    Lewis PO; Heil EL; Covert KL; Cluck DB
    J Clin Pharm Ther; 2018 Oct; 43(5):614-625. PubMed ID: 30003555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.
    Hammond J; Benigno M; Bleibdrey N; Ansari W; Nguyen JL
    Drugs Real World Outcomes; 2024 Jun; 11(2):273-283. PubMed ID: 38564101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
    Saravolatz L; Pawlak J; Johnson L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
    Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis.
    Li Z; Zhuang H; Wang G; Wang H; Dong Y
    BMC Infect Dis; 2021 Jan; 21(1):74. PubMed ID: 33446122
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
    Richter SS; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Kroeger JS; Biek D; Critchley IA; Diekema DJ; Doern GV
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4154-60. PubMed ID: 21709080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia?
    Kaye KS; Patel T; Drusano G
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31640979
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.